Endometriosis
Conditions
Keywords
Endometriosis, Dichloroacetate
Brief summary
This is a single-arm open label exploratory clinical trial to evaluate dichloroacetate (DCA) as a possible treatment for treatment of endometriosis-associated pain
Detailed description
Endometriosis is a chronic condition usually affecting women throughout their reproductive lives. It is defined as a growth of endometrial-like tissue (womb lining) outside the uterus (womb) and is associated with chronic pelvic pain that can be frequent and severe, resulting in tiredness, lower quality of life and difficulties in getting pregnant. Current treatments are unsatisfactory and there is an unmet need for new medical treatment for endometriosis. Research findings from our laboratory have shown that women with endometriosis have more lactate in their pelvis. In laboratory models of endometriosis, we have tested dichloroacetate (DCA), a compound used to treat metabolic disorders in children. Our results showed that DCA could stop the growth and survival of endometriosis cells and reduce lactate production. In our study we plan to investigate if we can we can recruit and retain women into a trial using this treatment. We will recruit 30 women aged 18 or over, with pelvic pain and a diagnosis of endometriosis within the last three years. Participants will complete informed consent, be willing to comply with the treatment and use contraception throughout the trial. We will recruit patients over six months at Royal Infirmary of Edinburgh. Women who consent will take a daily dose of DCA capsules for 12 weeks.
Interventions
DRUGDichloroacetate
6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
Sponsors
University of Nottingham
Ferring Pharmaceuticals
University of Birmingham
University of Edinburgh
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women aged 18 or over * Weight between 50 and 100kg * Pre-menopausal * Superficial peritoneal endometriosis (ASRM Stage I or II) at laparoscopy, performed within the last three years (and \>2 weeks from surgery) * Pelvic pain for longer than six months * Average pain score of ≥ 4 over the four weeks prior to treatment * Willing to comply with the treatment * Willing to use contraception throughout the trial * Willing and able to complete informed consent
Exclusion criteria
* Evidence of ovarian endometrioma or deep endometriosis (based upon current surgical staging or most recent imaging) * Women who are pregnant or actively trying to get pregnant * Known allergy or hypersensitivity to any excipient of DCA * Breastfeeding * Clinical evidence of pre-existing neuropathy * Diabetes * History of liver disease * History of kidney disease * Taking part in a CTIMP or other interventional non-CTIMP studies * Patient on combination antiretroviral therapy * History of malabsorption syndrome or substantial amount of small bowels or stomach removed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria. | Screening | The proportion of screened women who are eligible for the trial determined from the screening logs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the acceptability to patients of the proposed methods of recruitment, treatment, questionnaires and follow up. | Week 16 | Assessed by acceptability questionnaire at the end of study asking questions about participants' satisfaction with the methods of recruitment, treatment, questionnaires and follow up |
| To assess whether dichloroacetate is well-tolerated in women with endometriosis. | Throughout the treatment up to week 16 | Self-reported side effects during and after the treatment |
| To determine participants' compliance with treatment and to assess the tools used to measure it. | Throughout the treatment (Week 1- 12) | Assessed by self-report using treatment diaries to measure number of doses taken |
Countries
United Kingdom
Outcome results
None listed